Terms: = Prostate cancer AND GATA3, HDR, 2625, ENSG00000107485, MGC5445, MGC5199, MGC2346 AND Clinical Outcome
21 results:
1. High-dose-rate brachytherapy for prostate cancer: Rationale, current applications, and clinical outcome.
Strouthos I; Karagiannis E; Zamboglou N; Ferentinos K
Cancer Rep (Hoboken); 2022 Jan; 5(1):e1450. PubMed ID: 34164950
[TBL] [Abstract] [Full Text] [Related]
2. hdr brachytherapy boost using MR-only workflow for intermediate- and high-risk prostate cancer: 8-year results of a pilot study.
Lakosi F; Antal G; Pall J; Farkas A; Jenei T; Nagy D; Liptak J; Sipocz I; Pytel A; Csima M; Gulyban A; Toller G
Brachytherapy; 2021; 20(3):576-583. PubMed ID: 33478906
[TBL] [Abstract] [Full Text] [Related]
3. Primary yolk sac tumour of the prostate mimicking small round blue cell tumour.
Gui H; Kolster RA; Palmer MB; Brooks JS; Zhang M; Husson MA
Curr Oncol; 2019 Oct; 26(5):e707. PubMed ID: 31708666
[TBL] [Abstract] [Full Text] [Related]
4. Hypoxia and angiogenic biomarkers in prostate cancer after external beam radiotherapy (EBRT) alone or combined with high-dose-rate brachytherapy boost (hdr-BTb).
Bhattacharya IS; Taghavi Azar Sharabiani M; Alonzi R; Hoskin PJ
Radiother Oncol; 2019 Aug; 137():38-44. PubMed ID: 31059955
[TBL] [Abstract] [Full Text] [Related]
5. Improved survival for patients with prostate cancer receiving high-dose-rate brachytherapy boost to EBRT compared with EBRT alone.
Kent AR; Matheson B; Millar JL
Brachytherapy; 2019; 18(3):313-321. PubMed ID: 30846330
[TBL] [Abstract] [Full Text] [Related]
6. clinical outcome of high dose rate brachytherapy with external beam radiotherapy for high-risk prostate cancer: a single institutional retrospective study.
Shirotake S; Makino S; Suzuki K; Araki R; Kosaka T; Nishimoto K; Oyama M; Kato S
Jpn J Clin Oncol; 2019 Jan; 49(1):87-91. PubMed ID: 30476164
[TBL] [Abstract] [Full Text] [Related]
7. High-dose-rate brachytherapy boost for prostate cancer: Comparison of three different fractionation schemes.
Falk AT; Demontoy S; Chamorey E; Chand ME; Gautier M; Azria D; Zaki S; Chevallier D; Cham Kee DL; Hannoun-Lévi JM
Brachytherapy; 2017; 16(5):993-999. PubMed ID: 28754301
[TBL] [Abstract] [Full Text] [Related]
8. High Dose Rate Brachytherapy as Monotherapy for Localised prostate cancer: Review of the Current Status.
Tselis N; Hoskin P; Baltas D; Strnad V; Zamboglou N; Rödel C; Chatzikonstantinou G
Clin Oncol (R Coll Radiol); 2017 Jul; 29(7):401-411. PubMed ID: 28341241
[TBL] [Abstract] [Full Text] [Related]
9. prostate Specific Antigen (PSA) as Predicting Marker for clinical outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (hdr-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk prostate cancer.
Ecke TH; Huang-Tiel HJ; Golka K; Selinski S; Geis BC; Koswig S; Bathe K; Hallmann S; Gerullis H
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834929
[TBL] [Abstract] [Full Text] [Related]
10. Toxicity and quality of life after high-dose-rate brachytherapy as monotherapy for low- and intermediate-risk prostate cancer.
Aluwini S; Busser WM; Alemayehu WG; Boormans JL; Kirkels WJ; Jansen PP; Praag JO; Bangma CH; Kolkman-Deurloo IK
Radiother Oncol; 2015 Nov; 117(2):252-7. PubMed ID: 26409832
[TBL] [Abstract] [Full Text] [Related]
11. High-dose-rate brachytherapy as monotherapy for prostate cancer.
Demanes DJ; Ghilezan MI
Brachytherapy; 2014; 13(6):529-41. PubMed ID: 25085454
[TBL] [Abstract] [Full Text] [Related]
12. High-dose-rate interstitial brachytherapy as monotherapy for clinically localized prostate cancer: treatment evolution and mature results.
Zamboglou N; Tselis N; Baltas D; Buhleier T; Martin T; Milickovic N; Papaioannou S; Ackermann H; Tunn UW
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):672-8. PubMed ID: 22929859
[TBL] [Abstract] [Full Text] [Related]
13. Role of high dose rate brachytherapy in the treatment of prostate cancer.
Ghilezan M
Cancer Radiother; 2012 Sep; 16(5-6):418-22. PubMed ID: 22925490
[TBL] [Abstract] [Full Text] [Related]
14. External-beam radiation therapy and high-dose rate brachytherapy combined with long-term androgen deprivation therapy in high and very high prostate cancer: preliminary data on clinical outcome.
Martínez-Monge R; Moreno M; Ciérvide R; Cambeiro M; Pérez-Gracia JL; Gil-Bazo I; Gaztañaga M; Arbea L; Pascual I; Aristu J
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):e469-76. PubMed ID: 22284039
[TBL] [Abstract] [Full Text] [Related]
15. [clinical outcome in prostate cancer patients undergoing high-dose-rate brachytherapy with external beam radiotherapy in our institute].
Sakamoto N; Akitake M; Ikoma S; Ri K; Masuda K; Yoshikawa M; Iguchi A; Atsumi K; Matsumura T; Uehara S
Nihon Hinyokika Gakkai Zasshi; 2011 Jul; 102(4):621-7. PubMed ID: 21961274
[TBL] [Abstract] [Full Text] [Related]
16. Moderate dose escalation with single-fraction high-dose-rate brachytherapy boost for clinically localized intermediate- and high-risk prostate cancer: 5-year outcome of the first 100 consecutively treated patients.
Agoston P; Major T; Fröhlich G; Szabó Z; Lövey J; Fodor J; Kásler M; Polgár C
Brachytherapy; 2011; 10(5):376-84. PubMed ID: 21345741
[TBL] [Abstract] [Full Text] [Related]
17. clinical outcome in patients with prostate cancer treated with external beam radiotherapy and high dose-rate iridium 192 brachytherapy boost: a 6-year follow-up.
Kälkner KM; Wahlgren T; Ryberg M; Cohn-Cedermark G; Castellanos E; Zimmerman R; Nilsson J; Lundell M; Fowler J; Levitt S; Hellström M; Nilsson S
Acta Oncol; 2007; 46(7):909-17. PubMed ID: 17917823
[TBL] [Abstract] [Full Text] [Related]
18. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results.
Demanes DJ; Rodriguez RR; Schour L; Brandt D; Altieri G
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1306-16. PubMed ID: 15817332
[TBL] [Abstract] [Full Text] [Related]
19. The low alpha/beta ratio for prostate cancer: what does the clinical outcome of hdr brachytherapy tell us?
Wang JZ; Li XA; Yu CX; DiBiase SJ
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(4):1101-8. PubMed ID: 14575842
[TBL] [Abstract] [Full Text] [Related]
20. Early reduction in the aneuploidy at chromosomes 7 and 8 are significantly correlated with clinical effect in high-dose rate brachytherapy with external beam radiotherapy in localized prostate cancer.
Kasahara K; Taguchi T; Inoue K; Shuin T; Kariya S; Yoshida S; Furihata M
Int J Mol Med; 2001 Dec; 8(6):667-73. PubMed ID: 11712084
[TBL] [Abstract] [Full Text] [Related]
[Next]
